TRDA · Entrada Therapeutics, Inc. · Documents

Apr 29

Annual report to holders ARS

Annual report to holders

Apr 29

Proxy statement DEFA14A

Proxy statement

Apr 19

Proxy statement PRE 14A Meeting Jun 13, 2024

Proxy statement

Mar 13

Current report 8-K

Financial results

Mar 13

Annual report 10-K FY2023, ended Dec 31

Annual report for FY2023

Revenue $129.01M Net loss $6.69M Diluted EPS -$0.20

Jan 3

Current report 8-K Events of Dec 29

Director or officer change, or executive pay

Dec 6

Current report 8-K Events of Dec 5

Director or officer change, or executive pay

Nov 22

Current report 8-K

Regulation FD disclosure, Other events

Nov 7

Current report 8-K

Financial results

Nov 7

Quarterly report 10-Q FY2023 Q3, ended Sep 30

Quarterly report for FY2023 Q3

Revenue $43.74M Net income $35.46M Diluted EPS $1.02

Nov 1

Current report 8-K Events of Oct 26

Entered into a material agreement, Other events

Sep 29

Current report 8-K

Entered into a material agreement

Sep 21

Current report 8-K

Other events

Aug 10

Current report 8-K Events of Aug 4

Director or officer change, or executive pay

Aug 8

Quarterly report 10-Q/A Ended Mar 31

Quarterly report for the period ended Mar 31, 2023

Aug 8

Annual report 10-K/A Ended Dec 31

Annual report for the period ended Dec 31, 2022

Aug 8

Current report 8-K

Financial results

Aug 8

Quarterly report 10-Q FY2023 Q2, ended Jun 30

Quarterly report for FY2023 Q2

Revenue $18.17M Net loss $25.93M Diluted EPS -$0.78

Aug 1

Current report 8-K

Regulation FD disclosure, Other events

Jun 8

Current report 8-K Events of Jun 7

Director or officer change, or executive pay, Shareholder vote results

May 10

Current report 8-K

Financial results

May 10

Quarterly report 10-Q FY2023 Q1, ended Mar 31

Quarterly report for FY2023 Q1

Revenue $25.26M Net loss $6.67M Diluted EPS -$0.21

Apr 25

Proxy statement DEF 14A Meeting Jun 8, 2023

Proxy statement

Apr 25

Annual report to holders ARS

Annual report to holders

Apr 25

Proxy statement DEFA14A

Proxy statement

Apr 4

Current report 8-K

Director or officer change, or executive pay

Mar 6

Current report 8-K

Financial results

Mar 6

Annual report 10-K FY2022, ended Dec 31

Annual report for FY2022

Net loss $94.62M Diluted EPS -$3.02

Feb 9

Current report 8-K

Regulation FD disclosure, Other events

Jan 9

Current report 8-K

Other events

Dec 19

Current report 8-K

Other events

Dec 8

Current report 8-K Events of Dec 7

Entered into a material agreement, Unregistered sale of equity, Regulation FD disclosure

Nov 7

Current report 8-K

Financial results

Nov 7

Quarterly report 10-Q FY2022 Q3, ended Sep 30

Quarterly report for FY2022 Q3

Net loss $25.14M Diluted EPS -$0.80

Nov 1

Registration statement S-3

Registration statement

Aug 11

Current report 8-K

Current report

Aug 11

Quarterly report 10-Q FY2022 Q2, ended Jun 30

Quarterly report for FY2022 Q2

Net loss $23.18M Diluted EPS -$0.74

Jun 3

Current report 8-K Events of Jun 2

Shareholder vote results

May 12

Current report 8-K

Financial results

May 12

Quarterly report 10-Q FY2022 Q1, ended Mar 31

Quarterly report for FY2022 Q1

Net loss $21.67M Diluted EPS -$0.69

Apr 19

Proxy statement DEF 14A Meeting Jun 2, 2022

Proxy statement

Apr 19

Proxy statement DEFA14A

Proxy statement

Mar 22

Current report 8-K Events of Mar 16

Entered into a material agreement, New debt or off-balance-sheet obligation

Mar 15

Current report 8-K

Financial results

Mar 15

Annual report 10-K FY2021, ended Dec 31

Annual report for FY2021

Net loss $51.16M Diluted EPS -$8.16

Dec 9

Current report 8-K

Financial results

Dec 9

Quarterly report 10-Q FY2021 Q3, ended Sep 30

Quarterly report for FY2021 Q3

Net loss $14.43M Diluted EPS -$9.78

Nov 2

Current report 8-K Events of Oct 28

Charter or bylaw amendment, or fiscal year change

Oct 25

Registration statement S-1/A

Registration statement

Oct 8

Registration statement S-1

Registration statement